FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 315:141-147 July 17, 1986 Number 3 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We studied 25 patients with acute nonlymphocytic leukemia in second remission (20 patients) or third remission (5 patients) in whom autologous bone marrow transplantation was performed with use of marrow incubated ex vivo with the alkylating agent 4-hydroperoxycyclophosphamide. Patients received intensive cytoreductive therapy with busulfan and cyclophosphamide or cyclophosphamide and total body irradiation, followed by an infusion of marrow that had been collected in remission, treated with 4-hydroperoxycyclophosphamide, and cryopreserved. Four patients died from bacterial or fungal sepsis within the first month after transplantation, and one patient with persistent marrow hypoplasia died from gram-negative sepsis 155 days after infusion with autologous marrow. In the remaining patients, peripheral-blood levels of neutrophils in excess of 0.5 X 10(9) per liter and platelet counts over 50 X 10(9) per liter were attained at median intervals of 29 and 57 days after transplantation, respectively. Nine patients had leukemic relapses at 73 to 316 days (median, 182 days) after infusion of autologous marrow, for an actuarial relapse rate of 46 percent. Eleven patients (eight in second remission and three in third) remained in remission at a median of more than 400 days (range, greater than 230 to greater than 1653 days) after transplantation. The observed disease-free survival after transplantation with autologous marrow treated with 4-hydroperoxycyclophosphamide compares favorably with the results of syngeneic or allogeneic transplantation in similar groups of patients.

This article has been cited by other articles:

• Tallman, M. S., Gilliland, D. G., Rowe, J. M. (2005). Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163 [Abstract] [Full Text]  
• Wells, R. J., Adams, M. T., Alonzo, T. A., Arceci, R. J., Buckley, J., Buxton, A. B., Dusenbery, K., Gamis, A., Masterson, M., Vik, T., Warkentin, P., Whitlock, J. A. (2003). Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951. JCO 21: 2940-2947 [Abstract] [Full Text]  
• Giles, F. J., Keating, A., Goldstone, A. H., Avivi, I., Willman, C. L., Kantarjian, H. M. (2002). Acute Myeloid Leukemia. ASH Education Book 2002: 73-110 [Abstract] [Full Text]  
• Akpek, G., Ambinder, R. F., Piantadosi, S., Abrams, R. A., Brodsky, R. A., Vogelsang, G. B., Zahurak, M. L., Fuller, D., Miller, C. B., Noga, S. J., Fuchs, E., Flinn, I. W., O'Donnell, P., Seifter, E. J., Mann, R. B., Jones, R. J. (2001). Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma. JCO 19: 4314-4321 [Abstract] [Full Text]  
• Woods, W. G., Neudorf, S., Gold, S., Sanders, J., Buckley, J. D., Barnard, D. R., Dusenbery, K., DeSwarte, J., Arthur, D. C., Lange, B. J., Kobrinsky, N. L. (2001). A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 97: 56-62 [Abstract] [Full Text]  
• Matthews, D. C., Appelbaum, F. R., Eary, J. F., Fisher, D. R., Durack, L. D., Hui, T. E., Martin, P. J., Mitchell, D., Press, O. W., Storb, R., Bernstein, I. D. (1999). Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. Blood 94: 1237-1247 [Abstract] [Full Text]  
• Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E., Willman, C., Hurd, D. D., Bennett, J. M., Blume, K. G., Head, D. R., Wiernik, P. H. (1998). Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. NEJM 339: 1649-1656 [Abstract] [Full Text]  
• Gorin, N.C. (1998). Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia. Blood 92: 1073-1090 [Full Text]  
• Harousseau, J.-L., Cahn, J.-Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.-F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P., Herve, P. (1997). Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia. Blood 90: 2978-2986 [Abstract] [Full Text]  
• Ravindranath, Y., Yeager, A. M., Chang, M. N., Steuber, C. P., Krischer, J., Graham-Pole, J., Carroll, A., Inoue, S., Camitta, B., Weinstein, H. J., The Pediatric Oncology Group, (1996). Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in Childhood. NEJM 334: 1428-1434 [Abstract] [Full Text]  
• Brenner, M.K., Heslop, H.E., Rill, D., Li, C., Nilson, T., Roberts, M., Smith, C., Krance, R., Rooney, C. (1994). Gene Transfer and Bone Marrow Transplantation. Cold Spring Harb Symp Quant Biol 59: 691-697 [Abstract]